Record Sales

Showing 1332 articles
Business

AbCellera Biologics: A Valuation Crossroads After Volatile Returns

Shares of antibody discovery firm AbCellera Biologics (ABCL) present a complex picture for investors, with strong one-year gains overshadowed by steep declines over longer horizons. As the stock trades near $3.86, a significant gap emerges between its market price and some analyst fair value estimates, raising questions about its premium valuation in a challenging biotech market.

Business

Vodafone's Meteoric Rise: Is the Telecom Giant Still a Bargain After a 62% Surge?

Vodafone Group's shares have soared over 62% in the past year, dramatically outperforming the broader market. As the stock consolidates near £1.06, investors are grappling with a critical question: does the rally still have legs, or has the value opportunity evaporated? A deep dive into cash flow and valuation metrics suggests the story may be more complex than the headline numbers imply.